Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC

As precision medicine for liver cancer treatment becomes a reality, diagnostic tools are needed to help classify patients into groups for the best treatment choices. We have developed a molecular signature that could serve as a companion diagnostic and uses bulk or spatial transcriptomic data to identify a unique subclass of liver tumors. This subgroup of liver cancer patients derive limited benefit from the current standard of care and are expected to benefit from specialized directed therapies that are on the horizon.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2024-08-23
DOI
https://doi.org/10.1016/j.jhepr.2024.101186
Citations
16
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
5.72

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC

Catherine Cao, Junyan Tao, Sucha Singh, Théo Z. Hirsch et al.
16 citations
JHEP Reports
Thyroid Cancer Diagnosis and Treatment
5.72
article

Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC

Catherine Cao, Junyan Tao, Sucha Singh, Théo Z. Hirsch, Aatur Dilip Singhi, Brandon M. Lehrich, Silvia Liu, Satdarshan P. Monga, Evan R. Delgado, Long Pan, Jessica Zucman‐Rossi, Aaron Bell, Tyler M. Yasaka, Xiangnan Guan, Yulei Wang, Shan Lu, Y. Liu, Minakshi Poddar
article en
16 citations

Abstract

As precision medicine for liver cancer treatment becomes a reality, diagnostic tools are needed to help classify patients into groups for the best treatment choices. We have developed a molecular signature that could serve as a companion diagnostic and uses bulk or spatial transcriptomic data to identify a unique subclass of liver tumors. This subgroup of liver cancer patients derive limited benefit from the current standard of care and are expected to benefit from specialized directed therapies that are on the horizon.

JHEP ReportsVol. 6(12)
Inserm (FR), University of Pittsburgh (US), Université Paris Cité (FR), Sorbonne Université (FR), Centre de Recherche des Cordeliers (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Européen Georges-Pompidou (FR), Hôpital Européen (FR), University of Pittsburgh Medical Center (US)
University of Pittsburgh, National Institutes of Health, Center for Research Computing, University of Pittsburgh, Pittsburgh Liver Research Center, University of Pittsburgh, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Biomedical Imaging and Bioengineering
Zero hunger
Openalex Percentile: Top 3%
Thyroid Cancer Diagnosis and Treatment
5.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.